(20) Property, plant, and equipment
Accounting and measurement policies
Recognition and initial measurement
The Group receives monetary and non-monetary government grants. It does not exercise the option of recognizing non-monetary grants, such as allocated emission certificates, at fair value. Monetary grants related to assets are deducted from the respective carrying amount.
Advance payments are disclosed together with the assets under construction.
Subsequent measurement
Subsequent measurement is at amortized cost.
Property, plant and equipment is depreciated using the straight-line method over the useful life of the asset concerned, and the corresponding expenses are allocated to the respective functional costs. Depreciation of property, plant and equipment is primarily based on the following useful lives:
|
|
Useful life |
---|---|---|
Production buildings |
|
No more than 40 years |
Administration buildings |
|
No more than 40 years |
Plant and machinery |
|
6 to 25 years |
Operating and office equipment, other facilities |
|
3 to 10 years |
The useful lives of the assets are reviewed regularly and adjusted if necessary.
An impairment test is performed if there are indications of impairment. External and internal information is used in this context. In the event of impairment, an impairment loss is recognized under other operating expenses. Impairment losses are reversed up to amortized cost and reported in other operating income if the original reasons for impairment no longer apply.
Significant discretionary decisions and sources of estimation uncertainty
Determination of depreciation
Assumptions and estimates are required in determining the appropriate useful life and the expected residual value in order to calculate the amount of depreciation on property, plant and equipment. This applies in particular to the determination of the underlying remaining useful life. In making these estimates, the Group considers the useful lives of the property, plant and equipment derived from past experience, among other things.
Identification of a need to recognize impairment loss and reverse impairment loss
Discretionary decisions are required in the identification of objective evidence of impairment as well as in identifying the need to reverse impairment of property, plant and equipment.
€ million |
|
Land, land rights and buildings |
|
Plant and machinery |
|
Other facilities, operating and office equipment |
|
Construction in progress |
|
Total |
---|---|---|---|---|---|---|---|---|---|---|
Cost as of Jan. 1, 2023 |
|
5,976 |
|
6,228 |
|
1,879 |
|
2,429 |
|
16,513 |
Additions due to business combinations |
|
– |
|
– |
|
– |
|
– |
|
– |
Other Additions |
|
169 |
|
32 |
|
56 |
|
1,723 |
|
1,981 |
Disposals due to divestments/Reclassification to assets held for sale |
|
– |
|
– |
|
– |
|
– |
|
– |
Other Disposals |
|
-85 |
|
-93 |
|
-82 |
|
-18 |
|
-278 |
Transfers |
|
385 |
|
542 |
|
120 |
|
-1,053 |
|
-6 |
Currency translation difference |
|
-119 |
|
-84 |
|
-27 |
|
-37 |
|
-266 |
Dec. 31, 2023 |
|
6,326 |
|
6,625 |
|
1,946 |
|
3,045 |
|
17,943 |
|
|
|
|
|
|
|
|
|
|
|
Accumulated depreciation and impairment losses as of Jan. 1, 2023 |
|
-2,588 |
|
-4,319 |
|
-1,380 |
|
-21 |
|
-8,308 |
Depreciation |
|
-332 |
|
-389 |
|
-173 |
|
– |
|
-895 |
Impairment losses |
|
-1 |
|
-8 |
|
-2 |
|
-12 |
|
-23 |
Reversals of impairment losses |
|
– |
|
1 |
|
– |
|
– |
|
1 |
Disposals due to divestments/Reclassification to assets held for sale |
|
– |
|
– |
|
– |
|
– |
|
– |
Disposals |
|
67 |
|
88 |
|
77 |
|
– |
|
233 |
Transfers |
|
-9 |
|
1 |
|
5 |
|
3 |
|
1 |
Currency translation difference |
|
43 |
|
43 |
|
19 |
|
1 |
|
106 |
Dec. 31, 2023 |
|
-2,820 |
|
-4,584 |
|
-1,454 |
|
-29 |
|
-8,887 |
|
|
|
|
|
|
|
|
|
|
|
Net carrying amounts as of Dec. 31, 2023 |
|
3,506 |
|
2,042 |
|
492 |
|
3,016 |
|
9,056 |
|
|
|
|
|
|
|
|
|
|
|
Cost as of Jan. 1, 2024 |
|
6,326 |
|
6,625 |
|
1,946 |
|
3,045 |
|
17,943 |
Changes in the scope of consolidation |
|
3 |
|
3 |
|
2 |
|
2 |
|
10 |
Additions |
|
325 |
|
36 |
|
52 |
|
1,677 |
|
2,091 |
Reclassification to assets held for sale |
|
-185 |
|
-449 |
|
-61 |
|
-36 |
|
-731 |
Disposals |
|
-126 |
|
-179 |
|
-122 |
|
-15 |
|
-442 |
Transfers |
|
1,008 |
|
958 |
|
226 |
|
-2,211 |
|
-20 |
Currency translation difference |
|
128 |
|
83 |
|
12 |
|
38 |
|
261 |
Dec. 31, 2024 |
|
7,480 |
|
7,077 |
|
2,054 |
|
2,500 |
|
19,112 |
|
|
|
|
|
|
|
|
|
|
|
Accumulated depreciation and impairment losses as of Jan. 1, 2024 |
|
-2,820 |
|
-4,584 |
|
-1,454 |
|
-29 |
|
-8,887 |
Depreciation |
|
-365 |
|
-433 |
|
-184 |
|
– |
|
-982 |
Impairment losses |
|
-34 |
|
-21 |
|
-2 |
|
-28 |
|
-85 |
Reversals of impairment losses |
|
– |
|
– |
|
– |
|
– |
|
– |
Disposals due to divestments/Reclassification to assets held for sale |
|
132 |
|
387 |
|
49 |
|
12 |
|
580 |
Disposals |
|
95 |
|
169 |
|
119 |
|
6 |
|
389 |
Transfers |
|
3 |
|
17 |
|
-16 |
|
-4 |
|
– |
Currency translation difference |
|
-47 |
|
-46 |
|
-10 |
|
– |
|
-103 |
Dec. 31, 2024 |
|
-3,036 |
|
-4,510 |
|
-1,499 |
|
-42 |
|
-9,087 |
|
|
|
|
|
|
|
|
|
|
|
Net carrying amounts as of Dec. 31, 2024 |
|
4,445 |
|
2,567 |
|
556 |
|
2,457 |
|
10,025 |
The disposals due to divestments/Reclassification to assets held for sale related to the planned divestment of the Surface Solutions business. The additions from business combinations primarily related to the acquisition of Mirus Bio LLC, United States, and Unity SC, France (see Note (6) “Acquisitions and divestments”).
The individual additions to construction in progress in fiscal 2024 with an investment volume of more than € 50 million are presented below:
Business sector |
|
Investment project |
|
Country |
---|---|---|---|---|
Life Science |
|
Membrane factory |
|
Ireland |
Life Science |
|
Capacity for Drug Safety Testing Capacity (CTS) |
|
USA |
Healthcare |
|
Research Center |
|
Germany |
Healthcare |
|
Technology Center |
|
Germany |
Electronics |
|
Capacity for Semiconductor Solutions |
|
Taiwan |
Monetary grants amounted to € 78 million in fiscal 2024 (2023: € 88 million) and related to a number of different items. They comprised grants related to assets as well as grants related to income. Some of the aforementioned grants are tied to the recruitment of an agreed number of employees at the respective sites. The Group expects to satisfy the conditions for receiving the grants.
The impairments of € 85 million in fiscal 2024 (2023: € 23 million) included a mid-double-digit million-euro amount for the impairment of property, plant and equipment in France in the Life Science and Healthcare business sectors.